Turkey’s pharma market isn’t as high-profile as the oft-celebrated China or India. But that doesn’t mean big pharma aren’t looking for ways to beef up their operations in the country. As one of the world’s “pharmerging” markets, according to IMS Health, its growth prospects certainly outstrip the moribund Europe and sluggish U.S. And it’s also becoming a production hub.
Just this week, in fact, two big pharma companies unveiled new Turkish plans. Sanofi‘s ($SNY) generics maker Zentiva says it’s preparing to shift most of its production to a plant in Turkey, the Hürriyet Daily News reports. The Turkish facility would turn out a host of products now made elsewhere, mostly for export to other countries, Zentiva President Jérôme Silvestre said.
“We will turn our facilities in Lüleburgaz into a production base for generic drugs by shifting the production of many drugs from facilities abroad to Turkey,” Silvestre said (as quoted by Hurriyet).
These two developments follow another big foreign foray into Turkey earlier this year. Amgen ($AMGN) agreed in April to pay $700 million for the generics manufacturer Mustafa Nevzat.
Some Turkish industry leaders fear that foreign pharmas will end up controlling too much of the domestic business, including Abdi Ibrahim CEO Candan Karbagli. Her company has entertained offers to sell a minority stake, but rejects the idea of selling a majority position. “About 10 Turkish pharmaceutical firms have been acquired by foreigners in the last 10 years,” Karbagli said at a recent conference. “This is the way [we all may be taken over], one by one.”
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity